FDA Approves Six Cancer Therapies in Q2 2026, as Study Highlights Postmarketing Safety Updates

The FDA cleared six cancer therapies in the second quarter of 2026, expanding treatment options for breast, prostate, kidney, bladder, and blood cancers. Among them, sacituzumab govitecan moved into first-line triple-negative breast cancer, and capivasertib became the first targeted therapy for PTEN-deficient prostate cancer. A separate analysis of oncology drugs granted accelerated approval between 2011 and 2020 found that nearly 70% required postmarketing safety actions within four years, underscoring the importance of ongoing safety monitoring.

On June 25, 2026, the FDA approved sacituzumab govitecan-hziy (Trodelvy) for two first-line indications in triple-negative breast cancer. Based on the ASCENT-03 trial, the antibody-drug conjugate is now cleared for patients with unresectable locally advanced or metastatic disease who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. A second approval, supported by ASCENT-04/KEYNOTE-D19, covers use in combination with pembrolizumab (Keytruda) for patients whose tumors express PD-L1 with a combined positive score of 10 or greater.

Belzutifan (Welireg) was approved on June 12, 2026, in combination with pembrolizumab as adjuvant treatment for adults with clear cell renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy. The approval, based on the phase 3 LITESPARK-022 trial, expands the HIF-2α inhibitor into the post-surgical setting.

Also on June 12, capivasertib (Truqap) gained approval in combination with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer. The phase 3 CAPItello-281 trial demonstrated a median radiographic progression-free survival of 33.2 months with the AKT inhibitor versus 25.7 months for abiraterone alone. The FDA authorized a companion diagnostic, the VENTANA PTEN test, to identify eligible patients.

Palbociclib (Ibrance) was cleared for maintenance therapy in HR-positive, HER2-positive metastatic breast cancer, based on the PATINA trial, which showed a median progression-free survival of 44.3 months. This marks the first time a CDK4/6 inhibitor has been indicated for the HER2-positive population.

A separate review of 52 oncology drugs granted accelerated approval between 2011 and 2020 revealed that 69.2% required postmarketing safety actions, most often new warnings and precautions (63.5%). Boxed warnings were added to 11.5% of reviewed drugs, and the first safety action occurred at a median of 2.2 years after approval. Researchers noted that the frequency and early timing of these updates reflect the limited premarket safety data typically available for accelerated approvals. "Given the uncertainty at approval and the vulnerability of the patient population, rigorous postmarketing oversight is essential," the study authors concluded.